Astrazeneca PLC Common Stock (AZN) Gets Jefferies Higher Rating; 3 Analysts Are Bullish Fluidigm (FLDM) Last Week

Among 5 analysts covering Fluidigm (NASDAQ:FLDM), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Fluidigm had 22 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Fluidigm Corporation (NASDAQ:FLDM) earned “Hold” rating by Maxim Group on Thursday, August 27. Cowen & Co maintained Fluidigm Corporation (NASDAQ:FLDM) on Friday, August 4 with “Hold” rating. The firm has “Buy” rating given on Friday, February 5 by Mizuho. On Friday, August 5 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Cantor Fitzgerald given on Friday, October 30. Zacks upgraded the shares of FLDM in report on Friday, August 21 to “Sell” rating. The stock has “Neutral” rating by Mizuho on Friday, October 30. The stock of Fluidigm Corporation (NASDAQ:FLDM) has “Buy” rating given on Thursday, January 7 by Deutsche Bank. The rating was maintained by Mizuho with “Neutral” on Friday, August 7. Piper Jaffray maintained Fluidigm Corporation (NASDAQ:FLDM) rating on Thursday, February 8. Piper Jaffray has “Hold” rating and $6.1 target. See Fluidigm Corporation (NASDAQ:FLDM) latest ratings:

08/02/2018 Broker: Piper Jaffray Rating: Hold New Target: $6.1 Maintain
20/12/2017 Broker: Cowen & Co Rating: Hold New Target: $7.25 Maintain

Among 26 analysts covering AstraZeneca plc (ADR) (NYSE:AZN), 16 have Buy rating, 0 Sell and 10 Hold. Therefore 62% are positive. AstraZeneca plc (ADR) has $50 highest and $32 lowest target. $40.14’s average target is 16.05% above currents $34.59 stock price. AstraZeneca plc (ADR) had 44 analyst reports since July 31, 2015 according to SRatingsIntel. The stock of AstraZeneca PLC (NYSE:AZN) earned “Buy” rating by Cantor Fitzgerald on Friday, February 26. The stock of AstraZeneca PLC (NYSE:AZN) has “Buy” rating given on Friday, July 31 by S&P Research. The stock of AstraZeneca PLC (NYSE:AZN) earned “Hold” rating by Cowen & Co on Monday, October 16. Argus Research upgraded the stock to “Buy” rating in Monday, August 29 report. The stock of AstraZeneca PLC (NYSE:AZN) earned “Hold” rating by Nordea on Monday, November 2. Jefferies downgraded the shares of AZN in report on Monday, April 10 to “Hold” rating. The stock has “Buy” rating by Jefferies on Monday, September 12. On Friday, December 29 the stock rating was upgraded by JP Morgan to “Overweight”. As per Tuesday, December 1, the company rating was upgraded by Morgan Stanley. The firm has “Neutral” rating given on Wednesday, April 5 by UBS.

The stock increased 2.28% or $0.77 during the last trading session, reaching $34.59. About 4.32 million shares traded or 10.74% up from the average. AstraZeneca PLC (NYSE:AZN) has risen 19.45% since March 19, 2017 and is uptrending. It has outperformed by 2.75% the S&P500.

AstraZeneca PLC discovers, develops, makes, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide. The company has market cap of $86.46 billion. The Company’s marketed products comprise Arimidex, Casodex/Cosudex, Faslodex, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Imdur, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Symlin, Xigduo, and Xigduo XR for metabolic diseases. It has a 29.19 P/E ratio. The companyÂ’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Eklira Genuair/Tudorza Pressair, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalent and Synagis for infection diseases; Movantik/Moventig, Seroquel IR, Seroquel XR, Vimovo1, and Zomig for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases.

Analysts await AstraZeneca PLC (NYSE:AZN) to report earnings on April, 26. They expect $0.44 earnings per share, down 55.56% or $0.55 from last year’s $0.99 per share. AZN’s profit will be $1.10B for 19.65 P/E if the $0.44 EPS becomes a reality. After $1.30 actual earnings per share reported by AstraZeneca PLC for the previous quarter, Wall Street now forecasts -66.15% negative EPS growth.

Since October 16, 2017, it had 19 insider buys, and 0 insider sales for $5.69 million activity. LEVIN CAPITAL STRATEGIES – L.P. also bought $95,170 worth of Fluidigm Corporation (NASDAQ:FLDM) on Tuesday, February 27.

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research. The company has market cap of $249.56 million. It offers preparatory instruments, such as access array system, juno system, and callisto system; analytical instruments comprising biomark HD and EP1 systems; integrated fluidic circuits consisting of access array, juno genotyping, dynamic array, digital array, flex six, and callisto IFCs; and assays and reagents, including delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. It currently has negative earnings. The firm also provides C1 single-cell systems, polaris systems, C1 IFCs, polaris IFCs, helios/CyTOF 2 systems, maxpar reagents, imaging mass cytometer instruments and reagents, and laser ablation modules.

The stock decreased 1.83% or $0.12 during the last trading session, reaching $6.43. About 265,271 shares traded or 25.07% up from the average. Fluidigm Corporation (NASDAQ:FLDM) has declined 36.51% since March 19, 2017 and is downtrending. It has underperformed by 53.21% the S&P500.